Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine to Examine the Efficacy of RAMBA in Blocking Acne Pathogenic Gene Expression
NEW YORK, Dec. 19, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced entering into a research collaboration agreement with Weill Cornell Medicine to examine the ability of retinoic acid metabolism blocking agents (RAMBA) to block acne pathogenic gene expression in human keratinocytes, mouse skin, and carcinogenesis in mice.
Acne is the result, in part, of Propionibacterium acnes or ‘P. acnes’ growth in hair follicles, which leads to a defined set of pathogenic gene expression changes. The research collaboration will be conducted in three phases for a period of one year. Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and HOTH Senior Scientific Advisor, will be the Principal Investigator for the research collaboration.
Mr. Robb Knie, Chief Executive Officer of Hoth, commented, “Our research collaboration with Weill Cornell Medicine and Dr. Jonathan Zippin falls in line with our mission to research and develop new generation dermatological treatments. At the conclusion of our research together, we will work with the team at Weill Cornell Medicine to evaluate how to translate our findings into new therapies.”
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company’s proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth’s current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption “Risk Factors” in Hoth’s Form 10K for the period ending December 31, 2018, and Hoth’s other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
KCSA Strategic Communications
Valter Pinto / Daniela Guerrero
(212) 896-1254 / (212) 682-6300
View original content to download multimedia: http://www.prnewswire.com/news-releases/hoth-therapeutics-enters-into-research-collaboration-agreement-with-weill-cornell-medicine-to-examine-the-efficacy-of-ramba-in-blocking-acne-pathogenic-gene-expression-300977411.html
SOURCE Hoth Therapeutics, Inc.